{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"4.4","value":"3.9"},{"groupId":"OG001","lowerLimit":"2.0","upperLimit":"8.3","value":"4.2"},{"groupId":"OG002","lowerLimit":"1.4","upperLimit":"5.5","value":"2.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"description":"Time to tumor progression defined as the duration of time from start of treatment to time of progression. Response assessments were based on the longest diameter tumor measurements in accordance with Response Evaluation Criteria in Solid Tumors (RECIST).","dispersionType":"95% Confidence Interval","groups":[{"description":"Experimental: Sunitinib Malate (SU011248) Treatment","id":"OG000","title":"Liposarcoma Cohort Only"},{"description":"Experimental: Sunitinib Malate (SU011248) Treatment","id":"OG001","title":"Leiomyosarcoma Cohort Only"},{"description":"Experimental: Sunitinib Malate (SU011248) Treatment","id":"OG002","title":"Malignant Fibrous Histiocytoma (MFH) Cohort Only"}],"paramType":"MEDIAN","populationDescription":"All participants who completed the study","reportingStatus":"POSTED","timeFrame":"From On Treatment to Off Study - average of 6 months","title":"Participants' Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}